N-Desmethyl imatinib

N-Desmethyl imatinib (Norimatinib) is a c-Abl tyrosine kinase inhibitor. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways, and inhibits c-Abl-related neurodegenerative activity and neuroinflammation in vitro. N-Desmethyl imatinib can be used to study neurodegenerative diseases (such as Parkinson's disease) [1][2][3].

Product Specifications

CAS Number

[404844-02-6]

Product Name Alternative

Norimatinib; Imatinib metabolite N-Desmethyl imatinib

UNSPSC

12352005

Hazard Statement

H341, H351, H360, H362

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Imatinib-metabolite-N-Desmethyl-Imatinib.html

Purity

99.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(C)C(NC2=NC(C3=CC=CN=C3)=CC=N2)=C1)C4=CC=C(CN5CCNCC5)C=C4

Molecular Formula

C28H29N7O

Molecular Weight

479.59

Precautions

H341, H351, H360, H362

References & Citations

[1]Robert A Parise, et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791 (1-2) :39-44.|[2]Rymbai E, et al. The identification of c-Abl inhibitors as potential agents for Parkinson's disease: a preliminary in silico approach. Mol Divers. 2024 Dec;28 (6) :4051-4065.